What therapies may be considered for patients with heterozygous FH and persistently elevated LDL-C levels?
Patients with heterozygous FH and persistently elevated LDL-C levels may be considered for treatment with a PCSK9 inhibitor after a clinician-patient discussion of the net benefits versus the costs of such therapy. Additionally, other medical interventions that lower LDL-C levels via increased expression of LDL receptors may also be considered.